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ABSTRACT
Cytochrome P450 enzymes affected by artemisinin antimalarials 
– pharmacokinetic and pharmacogenetic aspects
With more than 500 million cases and at least 1 million deaths each year, malaria is a major 
global  health  problem.  The  main  problem  with  malaria  control  is  the  emerging  drug 
resistance among parasites causing the infection. Consequently, there is an urgent need for 
new drugs. The artemisinin endoperoxide antimalarials are highly effective, well tolerated 
and have become the most important class of drugs in the treatment of malaria. The parent 
compound,  artemisinin,  exhibits  remarkable  time-dependent  pharmacokinetics,  resulting 
from  a  pronounced  capacity  for  auto-induction.  Artemisinin  has  also  been  shown  to 
influence the cytochrome P450 (CYP) mediated metabolism of other drugs, increasing the 
risk of drug–drug interactions. The artemisinin antimalarials are recommended to be used in 
combination treatment. It is therefore crucial to elucidate which principal CYP enzymes are 
affected by these drugs. 
Using the cocktail approach it was demonstrated that several principal CYP enzymes 
were affected by the antimalarials artemisinin, dihydroartemisinin, artemether, arteether and 
artesunate  in  healthy  volunteers.  Metabolic  changes  were  moderate  but  in  several  cases 
shared by  all  five  endoperoxides  studied,  suggesting  a  class  effect.  At  therapeutic  doses 
artemisinin appeared to be associated with the strongest capacity for enzyme induction and 
inhibition.  The time-dependent metabolism of artemisinin was described in both healthy 
volunteers and malaria patients by a previously developed pharmacokinetic auto-induction 
model.  Further results  indicate  artemisinin  to induce the  activity  of  CYP2A6 in healthy 
subjects, but to which extent could not be demonstrated. Problems with studying induction 
of CYP2A6 using available probe compounds were highlighted. Pharmacogenetic data of 
genes  coding  for  principal  CYP enzymes  involved  in  antimalarial  treatment  obtained  in 
healthy Vietnamese volunteers,  were in general agreement with reports from other Asian 
populations. Artemisinin is suggested to be an alternative marker to assess the activity of 
CYP2B6. Further studies are needed to investigate the metabolic fate of artemisinin, and 
evaluate its potential use as an in vitro and in vivo CYP2B6 probe. 
In  conclusion,  this  thesis  has  contributed  with  pharmacokinetic  and  metabolic 
information on the artemisinin antimalarials, useful in the development of new derivatives 
and combination treatments. The potential of these drugs to affect CYP enzymes has to be 
considered  in  order  to  reduce  the  risk  of  drug-drug  interactions  and  achieve  optimal 
treatments of malaria.
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